Quarterly ResultMay 8, 2026, 07:16 AM
Boundless Bio Terminates HQ Lease for $10.5M; Q1 Net Loss $13.6M
AI Summary
Boundless Bio, Inc. reported a net loss of $13.6 million for the first quarter of 2026, an improvement from $15.8 million in the prior year. The company also announced the termination of its headquarters lease effective May 31, 2026, involving a $10.5 million cash outflow. Despite ongoing losses, Boundless Bio believes its $92.8 million in cash, cash equivalents, and short-term investments as of March 31, 2026, will be sufficient to fund operations for at least twelve months following the lease termination payment.
Key Highlights
- Boundless Bio terminated its headquarters lease effective May 31, 2026, incurring a $10.0M payment and retaining a $0.5M security deposit.
- Cash, cash equivalents, and short-term investments totaled $92.8M as of March 31, 2026.
- The company estimates existing cash will fund operations for at least 12 months after the lease termination payment.
- Net loss for Q1 2026 was $13.6M, an improvement from $15.8M in Q1 2025.
- Research and development expenses decreased to $9.7M in Q1 2026 from $12.1M in Q1 2025.
- General and administrative expenses decreased to $4.7M in Q1 2026 from $5.2M in Q1 2025.
- Net cash used in operating activities was $15.0M for Q1 2026, compared to $14.5M for Q1 2025.
- Accumulated deficit reached $273.2M as of March 31, 2026.